PAHC vs ZTS vs BFLY Stock Comparison

Phibro Animal Health, Zoetis and Butterfly Network Prices as of Oct 28, 2026 Peers: Industry group
ZTS Zoetis Inc.
$77.79 +8.9% 1M -46.5% 1Y
Market cap
$32.85B
P/E
12.6x
Revenue (TTM)
$9.52B
Div. yield
0.03%
Animal Health Healthcare
8 wins
BFLY Butterfly Network, Inc.
$7.82 -14.5% 1M +253.8% 1Y
Market cap
$1.94B
P/E
–
Revenue (TTM)
$112.15M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins

Head to Head

12 decided of 12

Zoetis leads on 8 of the 12 questions below (Zoetis 8, Phibro Animal Health 2, Butterfly Network 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionPAHCZTSBFLYLeader
Larger companyMarket capitalisation $1.58B $32.85B $1.94B ZTS
Cheaper on earningsLower P/E, profitable companies only 15.8x 12.6x -26.0x ZTS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 11.1x 13.3x — PAHC
Faster revenue growthRevenue growth, trailing twelve months +17.1% +1.5% +28.1% BFLY
More profitableNet margin, trailing twelve months 6.6% 27.5% -66.7% ZTS
Better return on capitalReturn on invested capital 14.2% 23.4% — ZTS
Less leveragedLower net debt / EBITDA 2.1x 1.8x — ZTS
Higher dividend yieldTrailing dividend yield 0.01% 0.03% 0.00% ZTS
Better 1-year returnPrice return, last 12 months -9.1% -46.5% +253.8% BFLY
Better 5-year returnAnnualised price return, 5 years +11.5%/yr -18.5%/yr -5.4%/yr PAHC
Less volatileAnnualised volatility, 1 year 55.5% 40.6% 115.0% ZTS
Higher overall scoreMean of the five percentile scores vs peers 68/100 72/100 45/100 ZTS

Percentile Scorecard

PAHCZTSBFLY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisPAHCZTSBFLY
Valuation 92 #52 of 625 88 #76 of 625 29 #161 of 227
Growth 85 #90 of 602 52 #290 of 602 67 #72 of 219
Profitability 85 #81 of 549 96 #23 of 549 33 #138 of 205
Financial Health 26 #485 of 654 34 #435 of 654 61 #92 of 237
Shareholder Returns 54 #171 of 367 90 #39 of 367 37 #86 of 135
Overall 68 72 45
  • PAHC ranked among 672 companies in Pharmaceuticals and Biotechnology
  • ZTS ranked among 672 companies in Pharmaceuticals and Biotechnology
  • BFLY ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodPAHCZTSBFLYSPY
1 month +6.1%+8.9%-14.5% +0.9%
3 months +2.5%-0.2%+10.3% +5.9%
6 months -27.8%-31.7%+58.9% +8.5%
Year to date +1.4%-38.2%+105.8% +13.3%
1 year -9.1%-46.5%+253.8% +12.4%
3 years +251.7%-50.1%+889.9% +88.1%
3 years, per year +52.1%-20.7%+114.8% +23.5%
5 years +72.7%-64.0%-24.2% +68.2%
5 years, per year +11.5%-18.5%-5.4% +11.0%
10 years +45.4%+60.2%— +263.4%
10 years, per year +3.8%+4.8%— +13.8%

Risk

MeasurePAHCZTSBFLYSPY
Volatility, 1Y 55.5%40.6%115.0% 12.7%
Downside volatility, 1Y 59.8%49.2%91.7% 12.7%
Beta vs S&P 500, 1Y 0.750.523.01 1.00
Return / volatility, 1Y -0.16-1.142.21 0.98
Max drawdown, 5Y -57.9%-72.0%-93.4% -25.4%
From 52-week high -36.4%-46.5%-21.3% -0.9%
52-week high $59.58$145.41$9.94 $779.14
52-week low $28.52$69.12$1.97 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultiplePAHCZTSBFLY
P/E now vs peer median 15.4xmedian 17.4x 12.4xmedian 17.4x -27.4xmedian 28.8x
P/S now vs peer median 1.0xmedian 9.1x 3.4xmedian 9.1x 16.6xmedian 3.0x
EV/EBITDA now vs peer median 8.1xmedian 17.1x 9.7xmedian 17.1x -24.0xmedian 17.4x
P/FCF now vs peer median 155.7xmedian 19.0x 13.9xmedian 19.0x -66.4xmedian 25.7x
P/B now vs peer median 4.0xmedian 2.2x 10.2xmedian 2.2x 9.8xmedian 2.4x
PEG now vs peer median 0.35median 0.34 1.32median 0.34 -1.01median 1.03

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsPAHCZTSBFLY
Revenue $1.52B $9.52B $112.15M
Gross profit $512.52M $6.81B $59.04M
Operating income $194.40M $3.59B -$79.38M
Net income $99.72M $2.62B -$74.85M
Free cash flow $9.87M $2.32B -$28.04M
R&D – $722.00M $38.10M
EPS (diluted) $2.43 $6.26 $-0.29
Cash & equivalents $61.42M $1.48B $124.66M
Total debt $2.49B $9.05B –
Shares (diluted) 40.96M 417.70M 262.10M
Enterprise value $1.26B $24.70B $1.39B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricPAHCZTSBFLY
P/E 15.4x 12.4x -27.4x
P/FCF 155.7x 13.9x -66.4x
P/Operating cash flow 22.3x 11.3x -77.5x
P/S 1.0x 3.4x 16.6x
P/B 4.0x 10.2x 9.8x
P/Tangible book 4.3x 14.4x 10.2x
EV/EBITDA 8.1x 9.7x -24.0x
EV/EBIT 10.7x 11.0x -21.9x
EV/Revenue 1.4x 4.2x 15.5x
EV/FCF 209.9x 17.1x -61.9x
EV/Operating cash flow 30.0x 13.9x -72.3x
PEG (3Y EPS CAGR) 0.35 1.32 -1.01

Growth

14 metrics
MetricPAHCZTSBFLY
Revenue growth (1Y) 17.1% 1.5% 28.1%
Revenue CAGR (3Y) 15.8% 5.0% 15.6%
Gross profit growth (1Y) 28.1% 1.8% 8.8%
Gross profit CAGR (3Y) 19.8% 5.7% 13.3%
Operating income growth (1Y) 76.0% -0.1% -14.8%
Operating income CAGR (3Y) 39.3% 5.2% 21.1%
Net income growth (1Y) 106.6% 0.6% -19.1%
Net income CAGR (3Y) 45.2% 5.7% 20.8%
EPS growth (1Y) 105.2% 7.7% -12.9%
EPS CAGR (3Y) 44.6% 9.4% 27.0%
Operating cash flow growth (1Y) -13.9% -4.6% 19.6%
Operating cash flow CAGR (3Y) 73.0% 12.4% 44.5%
Free cash flow growth (1Y) -76.4% 2.1% 12.2%
Free cash flow CAGR (3Y) 31.2% 21.7% 42.8%

Profitability

14 metrics
MetricPAHCZTSBFLY
Gross margin 33.8% 71.5% 52.6%
EBITDA margin 16.8% 42.8% -64.4%
Operating margin 12.8% 37.7% -70.8%
Pretax margin 9.0% 34.4% -66.7%
Net margin 6.6% 27.5% -66.7%
FCF margin 0.6% 24.3% -25.0%
Operating cash flow margin 4.5% 29.8% -21.4%
Return on equity 26.7% 82.0% -39.3%
Return on assets 6.8% 17.3% -26.3%
Return on invested capital 14.2% 23.4% –
Return on capital employed 16.8% 27.5% -35.1%
Asset turnover 1.0x 0.6x 0.4x
Cash conversion (OCF / net income) 0.7x 1.1x 0.3x
Stock comp / revenue 0.1% 1.0% 21.3%

Financial Health

11 metrics
MetricPAHCZTSBFLY
Debt / assets 41.1% 60.0% –
Debt / equity 1.6x 2.9x –
Net debt / EBITDA 2.1x 1.8x –
Debt / FCF 62.5x 3.9x –
Liabilities / assets 74.3% 79.1% 33.1%
Equity / assets 25.7% 20.9% 66.9%
Interest coverage 4.2x 15.1x -59.4x
Current ratio 3.0x 3.1x 4.1x
Quick ratio 1.1x 1.6x 2.7x
Cash ratio 0.3x 0.8x 2.1x
Altman Z-score 3.09 4.74 7.69

Shareholder Returns

7 metrics
MetricPAHCZTSBFLY
Dividend yield 1.3% 2.7% –
Net buyback yield – 11.3% -0.4%
Shareholder yield 1.3% 14.0% -0.4%
Payout ratio (earnings) 19.5% 34.0% –
Payout ratio (FCF) 197.3% 38.4% –
Dividend growth (1Y) 0.1% 6.1% –
Dividend CAGR (3Y) 0.0% 10.9% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusPAHCZTSBFLY
Forward P/E 11.1xFY2027 13.3xFY2026 –
EPS, next fiscal year $3.42FY2027 $5.86FY2026 $-0.10FY2026
EPS growth, next FY +6.2%FY2027 -8.6%FY2026 –
EPS growth, the year after +9.6% +13.0% –
Revenue, next fiscal year $1.53BFY2027 $9.57BFY2026 $114.50MFY2026
Revenue growth, next FY +0.6%FY2027 +1.0%FY2026 +17.3%FY2026
Revenue growth, the year after -0.2% -7.9% +26.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersPAHCZTSBFLY
Held by institutions 51.5% 94.7% 59.9%
Institutions holding 208 1,417 245
Change in shares held, QoQ +3.1% -2.6% +13.9%
Institutions buying 117 674 143
Institutions selling 73 582 59
Buyers to sellers 1.60 1.16 2.42

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

PAHCZTSBFLY
PAHC 1.00 0.61 0.12
ZTS 0.61 1.00 0.20
BFLY 0.12 0.20 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, PAHC, ZTS and BFLY?

Zoetis (ZTS) is the largest by market capitalisation: Phibro Animal Health (PAHC) $1.58B, Zoetis (ZTS) $32.85B, Butterfly Network (BFLY) $1.94B.

Which stock is cheaper, PAHC, ZTS and BFLY?

Zoetis (ZTS) trades on the lowest price-to-earnings ratio (Phibro Animal Health (PAHC) 15.8x, Zoetis (ZTS) 12.6x, Butterfly Network (BFLY) -26.0x). On next year's consensus earnings, Phibro Animal Health (PAHC) is cheapest (Phibro Animal Health (PAHC) 11.1x, Zoetis (ZTS) 13.3x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Butterfly Network (BFLY) grew revenue fastest over the trailing twelve months: Phibro Animal Health (PAHC) +17.1%, Zoetis (ZTS) +1.5%, Butterfly Network (BFLY) +28.1%.

Which company is more profitable?

Zoetis (ZTS) has the highest net margin (Phibro Animal Health (PAHC) 6.6%, Zoetis (ZTS) 27.5%, Butterfly Network (BFLY) -66.7%). On return on invested capital, Zoetis (ZTS) leads (Phibro Animal Health (PAHC) 14.2%, Zoetis (ZTS) 23.4%).

Which stock has performed better?

Over the past year Butterfly Network (BFLY) returned the most: Phibro Animal Health (PAHC) -9.1%, Zoetis (ZTS) -46.5%, Butterfly Network (BFLY) +253.8%. Over five years, Phibro Animal Health (PAHC) compounded fastest (Phibro Animal Health (PAHC) +11.5%/yr, Zoetis (ZTS) -18.5%/yr, Butterfly Network (BFLY) -5.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Zoetis (ZTS) has the highest dividend yield: Phibro Animal Health (PAHC) 0.01%, Zoetis (ZTS) 0.03%, Butterfly Network (BFLY) 0.00%. Butterfly Network (BFLY) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Zoetis (ZTS) has been the steadiest (Phibro Animal Health (PAHC) 55.5%, Zoetis (ZTS) 40.6%, Butterfly Network (BFLY) 115.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, PAHC, ZTS and BFLY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Zoetis (ZTS) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.